CAMBRIDGE, Mass. and GOSSELIES, Belgium, July 23, 2020 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development
1st July 2020 – Award-winning start-up e-peas continues to underline its reputation as the go-to supplier of advanced energy harvesting solutions, having just completed its latest funding round.
Wi
Unique 3M3 tissue regeneration technology platform generates multiple product candidates: autologous, off-the-shelf and miRNA/exosome
Mont-Saint Guibert, Belgium, 4 June, 2020: Novadip Biosciences (
Animal health company focused on combatting viral infections in livestock
LEUVEN, Belgium, May 28th, 2020 — ViroVet NV, a leading Belgian biopharmaceutical company active in the development of
– Initial data from the dose escalation portion of the Phase 1/2a trial in 21 cancer patients with advanced solid tumors shows EOS-850 was well tolerated with no dose-limiting toxicities observed –
–
Walloon biotech iTeos Therapeutics completes a new round of $125 million with historical investors and 5 new leading U.S. funds active in initial public offering (IPO). This is one of the largest
As of February 21st, Prof. Etienne Sokal, M.D., Ph.D., has stepped back from his operational role as Group CMO and will transition to the position of Chairman of Promethera®’s Scientific & Medical
Belgian biotechnology company ViroVet announced today that it has made its expertise, research staff as well as part of its research facility available to support COVID19 research and sample testing
Initial clinical data expected in 1H 2021
Cambridge, MA and Gosselies, Belgium – February 27, 2020 – iTeos Therapeutics Inc., a privately-held clinical-stage biotechnology company developing
Potentially pivotal trial for industry’s most-advanced cell-based therapy in severe liver diseases expected to generate results in H2 2023
Mont-Saint-Guibert, Belgium, and Tokyo, Japan, January 8th
